Skip to content

Efficacy and safety of oxycodone combined with lumboquadrate block for percutaneous nephroscopic anesthesia

Efficacy and safety of oxycodone combined with lumboquadrate block for percutaneous nephroscopic anesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091625
Enrollment
Unknown
Registered
2024-10-31
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Calculi of kidney and upper ureter

Interventions

Oxycodone Group (Group O):0.1mg/kg oxycodone was administered at induction of anesthesia and 30 minutes before the end of surgery
Sufentanil group (S group):0.1ug/kg sufentanil was administered at induction of anesthesia and 30 minutes before the end of surgery

Sponsors

Weihai Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Adults over 18 years old; (2) BMI: 18.5-27.9Kg/m^2; (3) ASA grade I-II; (4) percutaneous nephrolithotripsy; (5) The patient gave informed consent and voluntarily participated in this study, and signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of serious diseases of the heart, cerebrovascular, respiratory, liver, kidney and metabolic systems; (2) bradycardia (heart rate < 50 beats/min); (3) People with neuromuscular system diseases and mental diseases; (4) Patients with blood system diseases, abnormal coagulation function or taking anticoagulant drugs should not perform quadrate block anesthesia; (5) Previous history of oxycodone or other narcotic drugs allergies or abnormal surgical anesthesia recovery history; (6) Pregnant and lactating women; (7) The subject explicitly refuses to participate in the study; (8) Subjects that the researcher considers inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
VAS and NRS scores;

Secondary

MeasureTime frame
Average intraoperative propofol and remifentanil dosage per hour;MAP before anesthesia induction, before laryngeal mask placement, after laryngeal mask placement, 5 minutes after surgery, 30 minutes after surgery, at the end of surgery, when the laryngeal mask was removed, and when leaving the recovery room;HR before anesthesia induction, before laryngeal mask placement, after laryngeal mask placement, 5 minutes after the operation, 30 minutes after the operation, at the end of the operation, when the laryngeal mask was removed, and when leaving the recovery room;SpO2 before anesthesia induction, before laryngeal mask placement, after laryngeal mask placement, 5 minutes after surgery, 30 minutes after surgery, at the end of surgery, when the laryngeal mask was removed, and when leaving the recovery room;Cerebral oxygen saturation before anesthesia induction, before laryngeal mask placement, after laryngeal mask placement, 5 minutes after surgery, 30 minutes after surgery, and at the end of surgery;Postoperative recovery time;extubation time;Postoperative use of antagonists;Recovery room residence time;The amount of analgesic drugs was added within 24 hours after surgery;The occurrence of postoperative adverse reactions;

Countries

China

Contacts

Public ContactCong Jing

Weihai Central Hospital

congjing412@163.com+86 134 0672 2332

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026